=EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240)

Publication | Closed Access

DOI

Citations

References

2014

Year

Christie M. Ballantyne, Joel Neutel, Anne Cropp, William Duggan, Ellen Wang, David R. Plowchalk, Kevin Sweeney, Nitin Kaila, John Vincent, Harold Bays

Journal of the American College of Cardiology

Lipid DisorderCardiovascular DiseaseSafety Of BococizumabA RandomizedPharmacologyHyperlipidemiaPharmacotherapyDose-ranging StudyMedicineAtherosclerosisDyslipidemia